Form 4: MAIA Director Stan Smith Acquires Stock Options

MAIA Biotechnology Director Stan Smith acquired 24,844 stock options at an exercise price of $1.80, vesting immediately.

Summary

• Stan Smith, a Director of MAIA Biotechnology, Inc. (MAIA), acquired 24,844 stock options.
• The transaction date for the option grant was October 2, 2025.
• The stock options have an exercise price of $1.80 per share.
• These options were granted pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
• The options vest 100% on the date of the grant (October 2, 2025) and are exercisable as of that date.
• The expiration date for these stock options is October 2, 2035.
• Mr. Smith beneficially owns these securities indirectly through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 7

Explanation: The grant of stock options to a director, vesting immediately, indicates management's continued commitment and aligns their interests with long-term shareholder value, which is generally a positive signal.

Positives

• The grant of stock options to a director increases their equity stake and aligns their interests with long-term shareholder value.
• Immediate vesting of the options demonstrates confidence and provides immediate incentive for the director.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of director's financial interests with shareholder returns, potentially leading to more focused decision-making for long-term value creation.
• Management/Employees: Reinforces the company's compensation structure and commitment to retaining key personnel through equity incentives.

Next Steps

• The director may choose to exercise the vested stock options at any time before the expiration date of October 2, 2035.

Key Dates

Recommendation

The grant of stock options to a director is a positive signal, indicating insider confidence and aligning management's interests with shareholders. While not an open market purchase, it suggests a commitment to the company's future. This event alone is generally not sufficient for a 'buy' recommendation without further fundamental analysis, but it supports a 'hold' position for existing investors and provides a favorable data point for potential investors.

Keywords

MAIA Biotechnology, MAIA, Stan Smith, Stock Options, Insider Transaction, Director Compensation, Equity Incentive Plan, Biotechnology